Background <p>Patients with non-small cell lung cancer (NSCLC) exhibit heterogeneous responses to immunotherapy (IT) with high resistance rates, highlighting the need for precise biomarkers of treatment outcomes.</p> Methods <p>In a prospective cohort study, we longitudinally assessed liquid biopsy samples from patients with NSCLC undergoing IT at four distinct time points (T1 pretreatment, T2 post-second cycle, T3 6 months, and T4…
Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC
Journal for ImmunoTherapy of Cancer | | Onieva, J. L., Perez-Ruiz, E., Figueroa-Ortiz, L. C., Jurado, J. M., Martinez, B., Carlos Benitez, J., Rueda-Dominguez, A., Barragan, I.
Topics: lung-cancer, skin-cancer, blood-cancer, immunotherapy, targeted-therapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer